Hemab Therapeutics has concluded an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders. The investment round was spearheaded by Sofinnova Partners and saw contributions from a global asset management company. New investors, along with a sovereign wealth fund and Avoro Capital Advisors, joined the round, with continued support from existing stakeholders Access Biotechnology, Avoro Ventures, Deep Track Capital, Invus, Maj Invest Equity, Novo Holdings, R ...